1:23
ESH MM 2018 | Targeting BCMA with bispecific antibodies in R/R myeloma
Saad Usmani
1:32
ESH MM 2018 | Immunotherapeutics against multiple myeloma: it’s all about BCMA
Enrique Ocio
1:35
ESH MM 2018 | Monoclonal antibodies: current and future potential
Saad Usmani
2:45
ESH MM 2018 | Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
Heinz Ludwig
1:09
iwNHL 2018 | Non-hodgkin lymphoma advances in 2018
Steven Rosen
3:29
SOHO 2018 | Novel drugs and targets in MDS
Valeria Santini
6:20
Myeloma 2018 | Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
Florian Bassermann et al.
2:41
EHA 2018 | Immunotherapy in AML: azacitidine plus checkpoint inhibitors
Naval Daver
1:22
ASCO 2018 | ALL: recent immunotherapeutic developments
Ryan Cassaday
1:27
EHA 2018 | CAR T-cells in ALL: an overview
Oliver Ottmann
2:22
EMN 2018 | New strategies for durable remission in MM
Niels van de Donk
2:40
ASCO 2018 | Monoclonal antibodies: the future of MM treatment?
Faith Davies
2:12
EHA 2018 | T-cell redirecting therapies for R/R multiple myeloma
Niels van de Donk
3:01
EHA 2018 | MM treatment in the US vs. Europe: multi-drug regimens & cellular therapies
Ola Landgren
5:35
EHA 2018 | Contemporary designs for multiple myeloma treatment
Gareth Morgan
2:24
ASH 2017 | Novel ALL treatment strategies: blinatumomab
Elias Jabbour
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals